257 related articles for article (PubMed ID: 15300147)
61. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
Hurle R; Losa A; Manzetti A; Lembo A
Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
[TBL] [Abstract][Full Text] [Related]
62. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
63. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
[TBL] [Abstract][Full Text] [Related]
64. Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
Kikuchi E; Hayakawa N; Fukumoto K; Shigeta K; Matsumoto K
Int J Urol; 2020 Feb; 27(2):108-116. PubMed ID: 31793703
[TBL] [Abstract][Full Text] [Related]
65. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
Lammers RJ; Witjes JA
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1903-16. PubMed ID: 21110757
[TBL] [Abstract][Full Text] [Related]
66. Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.
Becker REN; Kates MR; Bivalacqua TJ
Urol Clin North Am; 2020 Feb; 47(1):15-21. PubMed ID: 31757296
[TBL] [Abstract][Full Text] [Related]
67. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
Herr HW
J Urol; 2012 Feb; 187(2):435-7. PubMed ID: 22177154
[TBL] [Abstract][Full Text] [Related]
68. Intravesical bacille Calmette-Guérin in the treatment of carcinoma in situ or high-grade superficial bladder carcinoma after radiotherapy for bladder carcinoma.
Palou J; Sánchez-Martín FM; Rosales A; Salvador J; Algaba F; Vicente J
BJU Int; 1999 Mar; 83(4):429-31. PubMed ID: 10210566
[TBL] [Abstract][Full Text] [Related]
69. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N
Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163
[TBL] [Abstract][Full Text] [Related]
70. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
71. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
72. Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
J Urol; 2010 Nov; 184(5):1920-4. PubMed ID: 20846678
[TBL] [Abstract][Full Text] [Related]
73. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
74. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
Urology; 2017 May; 103():149-153. PubMed ID: 28163086
[TBL] [Abstract][Full Text] [Related]
75. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
76. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
[TBL] [Abstract][Full Text] [Related]
77. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
[TBL] [Abstract][Full Text] [Related]
78. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
Dalbagni G; Russo P; Bochner B; Ben-Porat L; Sheinfeld J; Sogani P; Donat MS; Herr HW; Bajorin D
J Clin Oncol; 2006 Jun; 24(18):2729-34. PubMed ID: 16782913
[TBL] [Abstract][Full Text] [Related]
79. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
80. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
